A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Tongji Hospital
Tongji Hospital
Seoul National University Hospital
M.D. Anderson Cancer Center
Seoul National University Hospital
Seoul National University Hospital
Peking University
National Cancer Institute (NCI)
Seoul National University Hospital
National Health Research Institutes, Taiwan
University Hospital, Angers
Boston Scientific Corporation
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Fujian Medical University Union Hospital